A Dinuclear Ruthenium(II) Schiff Base Complex with Dissimilar Coordination: Synthesis, Characterization, and Biological Activity

被引:18
作者
Kahrovic, Emira [1 ]
Zahirovic, Adnan [1 ]
Turkusic, Emir [1 ]
Bektas, Sabaheta [2 ]
机构
[1] Univ Sarajevo, Fac Sci, Dept Chem, Sarajevo 71000, Bosnia & Herceg
[2] Inst Publ Hlth Canton Sarajevo, Sarajevo 71000, Bosnia & Herceg
来源
ZEITSCHRIFT FUR ANORGANISCHE UND ALLGEMEINE CHEMIE | 2016年 / 642卷 / 06期
关键词
Schiff bases; Ruthenium; Dinuclear complex; CT DNA; Antimicrobial activity; OXIDATION; HYDROXIDE; IONS;
D O I
10.1002/zaac.201600008
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
A dinuclear Schiff base Ru-II complex derived from 5-chlorosalicylaldehyde and 2-aminopyridine was synthesized. The structure of the compound was analyzed by mass spectrometry as well as IR, UV/Vis, and H-1 NMR spectroscopy, along with chemical analysis, as well as magnetic, cyclovoltammetric and conductivity measurements. Two Ru-II atoms are octahedrally coordinated by azomethine and pyridine nitrogen atoms from two tridentate monobasic Schiff bases and bridging phenol oxygen atoms. The formula of the complex is [Ru2L2Cl2(Et2NH)(H2O)] [L = N-(2-pyridyl)-5-chlorosalicylidene-imine and Et2NH = isodiethylamine]. The Ru-II atoms in the dinuclear neutral complex species have different coordination environments, RuN3O2Cl and RuN2O3Cl. Interaction with CT DNA showed moderate hydrophobic binding. The compound demonstrates strong activity against methicillin-resistant Staphylococcus aureus, methicillin-sensitive Staphylococcus aureus, and especially Enterococcus faecalis. Microbiological tests showed significant inhibition of growth and ability to kill pathogens, similar or even improved compared to reference antibiotics vancomycin.
引用
收藏
页码:480 / 485
页数:6
相关论文
共 16 条
[1]  
Abbas K, 2005, Z NATURFORSCH A, V60, P667
[2]   Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates [J].
Bergamo, A. ;
Gaiddon, C. ;
Schellens, J. H. M. ;
Beijnen, J. H. ;
Sava, G. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2012, 106 (01) :90-99
[3]  
Choi T.L., 2003, Angewandte Chemie, V115, P1785
[4]   Ruthenium metallopharmaceuticals (vol 232, pg 69, 2002) [J].
Clarke, MJ .
COORDINATION CHEMISTRY REVIEWS, 2003, 236 (1-2) :207-+
[5]  
Dueke-Eze C.U., 2011, Afr. J. Pure Appl. Chem., V5, P13
[6]   HYDROXIDE ION AS A REDUCING AGENT FOR CATIONS CONTAINING 3 RUTHENIUM ATOMS IN NONINTEGRAL OXIDATION STATES [J].
EARLEY, JE ;
FEALEY, T .
INORGANIC CHEMISTRY, 1973, 12 (02) :323-327
[7]  
Grela K., 2002, Angew. Chem, V114, P4210, DOI DOI 10.1002/1521-3757(20021104)114:21<4210::AID-ANGE4210>3.0.CO
[8]  
2-J
[9]   Determination of ruthenium in pharmaceutical compounds by graphite furnace atomic absorption spectroscopy [J].
Jia, XJ ;
Wang, TB ;
Bu, XD ;
Tu, QA ;
Spencer, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 41 (01) :43-47
[10]  
Kahrovic E., 2014, J CHEM CHEM ENG, V8, P335